Press Releases

Date Title and Summary Additional Formats
Toggle Summary Aravive Biologics Initiates Phase 1 Study of Novel GAS6-AXL Pathway Inhibitor, AVB-S6-500
Aravive Biologics, Inc., a clinical-stage biotechnology company focused on development of treatments for cancer and fibrotic diseases, today announced the initiation of a Phase 1 clinical trial of AVB-S6-500 (previously referred to as Aravive-S6).  The study is being conducted in the United States
Toggle Summary Aravive Biologics and WuXi Biologics to Form Strategic Manufacturing Collaboration Following Successful IND Filing for AVB-S6-500
Aravive Biologics, Inc. and WuXi Biologics (WuXi Bio, 02269.HK) today announced plans to expand their biologics manufacturing collaboration, based on the rapid success achieved in the process development, scale-up and cGMP manufacture of Aravive’s lead drug candidate, AVB-S6-500 (previously